The Net Tightens

Chapter 134: The Net Tightens The email was waiting before Leah's coffee had gone cold, marked URGENT in Priya Sharma's careful subject-line style and timed badly enough to feel like a hand closing around her throat. Catherine Thorne had not yet signed the statement. The notary had not yet called back. Leah had spent the night converting a mother's confession into language that could survive Pemberton's knives, and now Thorne Group wanted Catherine Marsh in Conference Room 34-B in forty-five minutes with her NexGen working files. Sebastian Costa would be joining by video. Leah read the email twice, not because she misunderstood it, but because each detail carried a different threat. Sebastian did not attend analyst meetings. Short notice was not courtesy; it was pressure. If Pemberton had seen even a shadow of yesterday's townhouse visit, this would be where he tested it. She opened the three memos on her laptop, checked the forty-one pages she already knew by heart, and walked to the conference room with Catherine Marsh's badge clipped straight and Leah Chen's pulse kept under lock. The room was smaller than she expected: eight chairs, a screen, Lexington Avenue beyond the glass. David Choi sat with his laptop open and his face arranged into neutrality. Beside him, Howard Pemberton waited with a paper cup of coffee and the expression of a man who had never needed to raise his voice to ruin a life. Leah paused for half a second. No more. "Ms. Marsh," Pemberton said warmly. "Please. Sit. I understand you've done excellent work on NexGen." "Thank you, Mr. Pemberton." Leah placed her files on the table. "I submitted the complete analysis to David Thursday evening." "I've read it. Thorough. Precise." His eyes stayed on her face, not the files. "You identified five discrepancies by cross-referencing investor disclosures against raw Phase III data." "Yes." "All upward adjustments." "Each one made the drug appear more effective than the source data supported. Four were within plausible variance. The fifth, the 3.7 percent overall response adjustment, is mathematically improbable for the patient sample size." "Improbable," he repeated, tasting the word. "Not impossible. Not fraudulent." "I'm an analyst. I report what the data shows. Fraud, error, or coincidence is a legal question." Pemberton smiled without warmth. "Careful. David says you're careful. Priya says the same. Careful with documents, numbers, words." He leaned back. "Were you raised that way?" The trap was soft enough to look like conversation. "Yes," Leah said. "Where?" "Virginia. Outside Charlottesville. My father taught high school history. My mother was a librarian." "And Georgetown after UVA. Public policy to clinical data analysis at a Fortune 500 company." His smile widened by a fraction. "An interesting path." The screen came alive before Leah had to answer. Sebastian Costa appeared in a glass-walled office above the Hudson, sharp-featured and strained in the particular way of powerful men discovering that numbers could bleed. "Good morning," he said. "David. Howard. Ms. Marsh." Pemberton's tone shifted into client warmth. "Sebastian. We're reviewing the NexGen analysis before the SEC response team files preliminary findings." "Then let's get to it." Sebastian looked straight at Leah through the screen. "David tells me you identified the discrepancies independently." "I did." "No one directed your attention to NexGen." "Correct." "Interesting. Three review teams looked at that data over eighteen months. Internal audit, external compliance, and the SEC's preliminary inquiry. None flagged the 3.7 percent adjustment. You found it in three weeks." David kept his eyes on his laptop. Pemberton's fingers rested beside his cup. Leah understood then that the meeting had never been about NexGen. It was about Catherine Marsh: whether she was merely bright, or placed, or dangerous. "The earlier reviews focused on aggregate outcomes," Leah said. "I compared investor disclosures against patient-level data. Different methodology. Different results." "Where did you learn that methodology?" "Forensic accounting. Cross-reference public disclosures against source records." "That's fraud work," Sebastian said. Silence entered the room like another attorney. Pemberton broke it. "The SEC response is due Friday. David?" "Preliminary findings Wednesday. Full response Friday," David said. "Good." Pemberton looked back to Leah. "Your analysis will be included with attribution. Anything else before we conclude?" She could downplay it and leave alive inside the company for another day. She could let Sebastian's accusation define her. Or she could do what Catherine Marsh was never supposed to do: make the room move. "One thing," Leah said. "NexGen is not isolated. I found similar directional adjustments in at least four other Thorne Foundation-funded clinical trials, including Veritas Labs and three studies between 2000 and 2018. Same below-threshold methodology. Same absence of documentation. If the SEC is investigating NexGen, they should know the pattern may be systemic." The word hit. Pemberton did not blink. But his right index finger tapped the table once beside the coffee cup, a tiny, involuntary strike. Sebastian went pale on the screen. "Systemic," Sebastian said. "The pattern exists across multiple trials, years, and investigators," Leah said. "Whether it's systemic is for investigators to determine." Sebastian glanced at Pemberton, quick and sharp. Did you know? The question crossed the screen without sound. Pemberton's face answered nothing and everything. "Thank you, Ms. Marsh," Pemberton said. "That will be all." Leah gathered her files. At the door, he spoke again. "Ms. Marsh." She stopped without turning. "In forty-two years of practice, I've learned the most dangerous people in an organization are not the ones who make mistakes. They're the ones who find them." The warning settled over her shoulders like a tailored coat. "Good day, Mr. Pemberton," Leah said, and left before her hands could betray her. She made it four blocks north before the tremor reached her fingers. By then the May morning had swallowed her into ordinary Manhattan: coffee carts, taxis, people who did not know the scope of an SEC investigation had just widened inside a room above Lexington Avenue. She stopped under a bank awning and texted Ethan. Meeting with Pemberton and Sebastian. Expanded SEC scope to four additional Foundation trials. Pemberton tapped once when I said systemic. He knows. Ethan answered in twelve seconds. How bad? Bad. But useful. We're past careful. Agreed. Leah put the phone away and did not go back upstairs. She walked to a coffee shop on Third Avenue, took the corner table facing the door, and opened the draft testimony Catherine had promised to sign. Catherine's words were still raw in the margins: Martha told me they were dead. Pemberton brought papers. Richard started to doubt. Now Leah understood the shape of the day. Pemberton knew Catherine Marsh was wrong. Sebastian knew the acquisition risk had spread. Catherine Thorne was about to become a written witness. The SEC response had a Friday deadline. The net was tightening from every side. Leah began typing the notarized statement's final paragraph while watching the door, because the next knock would not wait for the case to be perfect.